Key statistics
On Thursday, Fulcrum Therapeutics Inc (FULC:NMQ) closed at 2.97, 3.85% above its 52-week low of 2.86, set on Nov 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.02 |
---|---|
High | 3.08 |
Low | 2.96 |
Bid | 2.97 |
Offer | 3.10 |
Previous close | 2.99 |
Average volume | 966.42k |
---|---|
Shares outstanding | 62.40m |
Free float | 61.39m |
P/E (TTM) | -- |
Market cap | 186.58m USD |
EPS (TTM) | -0.3098 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 20:59 GMT.
More ▼
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024
- Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference
- Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
- Fulcrum Therapeutics to Participate in Upcoming September Conferences
- Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024
- Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET
- Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
More ▼